Evidence map›Paper›PMID 28144535›Full record

ArticleBeilstein journal of nanotechnology2016

Chitosan-based nanoparticles for improved anticancer efficacy and bioavailability of mifepristone.

Huijuan Zhang, Fuqiang Wu, Yazhen Li, Xiping Yang, Jiamei Huang, Tingting Lv, Yingying Zhang, Jianzhong Chen, Haijun Chen, Yu Gao and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Beilstein journal of nanotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Nanocarriers as Magic Bullets in the Treatment of Leukemia.Nanomaterials (Basel, Switzerland) · 2020
    Review
  15. Article
  16. The potency of chitosan-basedVeterinary world · 2019
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Huijuan ZhangCollege of Chemistry, Fuzhou University, Fuzhou 350108, China.
Fuqiang WuCollege of Chemistry, Fuzhou University, Fuzhou 350108, China.
Yazhen LiCollege of Chemistry, Fuzhou University, Fuzhou 350108, China.
Xiping YangCollege of Chemistry, Fuzhou University, Fuzhou 350108, China.
Jiamei HuangCollege of Chemistry, Fuzhou University, Fuzhou 350108, China.
Tingting LvCollege of Chemistry, Fuzhou University, Fuzhou 350108, China.
Yingying ZhangCollege of Chemistry, Fuzhou University, Fuzhou 350108, China.
Jianzhong ChenSchool of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China.
Haijun ChenCollege of Chemistry, Fuzhou University, Fuzhou 350108, China.
Yu GaoCollege of Chemistry, Fuzhou University, Fuzhou 350108, China.
Guannan LiuCollege of Life Sciences, China Jiliang University, Hangzhou, Zhejiang, 310018, China.
Lee JiaCollege of Chemistry, Fuzhou University, Fuzhou 350108, China.
Fuzhou University · CNChina Jiliang University · CNFujian University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to its well-known abortifacient effect, mifepristone (MIF) has been used as an anticancer drug for various cancers in many studies with an in-depth understanding of the mechanism of action. However, application of MIF is limited by its poor water solubility and low oral bioavailability. In this work, we developed a drug delivery system based on chitosan nanoparticles (CNs) to improve its bioavailability and anticancer activity. The MIF-loaded chitosan nanoparticles (MCNs) were prepared by convenient ionic gelation techniques between chitosan (Cs) and tripolyphosphate (TPP). The preparation conditions, including Cs concentration, TPP concentration, Cs/MIF mass ratio, and pH value of the TPP solution, were optimized to gain better encapsulation efficiency (EE) and drug loading capacity (DL). MCNs prepared with the optimum conditions resulted in spherical particles with an average size of 200 nm. FTIR and XRD spectra verified that MIF was successfully encapsulated in CNs. The EE and DL of MCNs determined by HPLC were 86.6% and 43.3%, respectively. The in vitro release kinetics demonstrated that MIF was released from CNs in a sustained-release manner. Compared with free MIF, MCNs demonstrated increased anticancer activity in several cancer cell lines. Pharmacokinetic studies in male rats that were orally administered MCNs showed a 3.2-fold increase in the area under the curve from 0 to 24 h compared with free MIF. These results demonstrated that MCNs could be developed as a potential delivery system for MIF to improve its anticancer activity and bioavailability.

Indexed as

anticancerchitosandrug deliverymifepristonenanoparticlespharmacokineticssustained release

Identifiers

PMID28144535
PMCPMC5238647
OpenAlexW2557514660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.